AstraZeneca (AZN) Form 3/A Initial statement of insider ownership (amended)

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

ASTRAZENECA PLC

(Last) (First) (Middle)

1 FRANCIS CRICK AVENUE

CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE X0 CB2 0AA

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/02/2019

3. Issuer Name and Ticker or Trading Symbol
Viela Bio, Inc. [ VIE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
10/02/2019

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10	I	See footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-1 Preferred Stock	(2)	(3)	Common Stock	14,225,324	(4)	I	See footnote(1)

1. Name and Address of Reporting Person^*

ASTRAZENECA PLC

(Last) (First) (Middle)

1 FRANCIS CRICK AVENUE

CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE X0 CB2 0AA

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

AstraZeneca UK LTD

(Last) (First) (Middle)

1 FRANCIS CRICK AVENUE

CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE X0 CB2 0AA

(City) (State) (Zip)

Explanation of Responses:

1. All of these securities are owned by AstraZeneca UK Limited, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca UK Limited, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.

2. The shares of preferred stock will automatically convert into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.

3. Not applicable.

4. The shares of preferred stock will automatically convert into the Issuer's common stock on a 1-for-1 basis immediately upon completion of the Issuer's initial public offering.

Remarks:

This Form 3 is being amended to add AstraZeneca UK Limited as an additional reporting person.

	AstraZeneca PLC, By: /s/ Adrian Kemp	10/09/2019
	AstraZeneca UK Limited, By: /s/ Adrian Kemp	10/09/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.